Endo Pharmaceuticals to Announce Third Quarter 2011 Financial Results on October 27, 2011

CHADDS FORD, Pa., Oct. 12, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) will announce its third quarter 2011 financial results on October 27, 2011 and will host a conference call and webcast at 10:00 a.m. ET that day to discuss these results.  

David P. Holveck, president and CEO of Endo, Julie McHugh, chief operating officer, Dr. Ivan Gergel, executive vice president of R&D, Alan Levin, executive vice president and chief financial officer, and Blaine Davis, vice president, corporate affairs will host the call.

Investors and other interested parties may call 800-901-5241 (domestic) or 617-786-2963 (international) and enter passcode 11948354.  Please dial in 10 minutes prior to the scheduled start time.

A replay of the call will be available from October 27 at 12:00 p.m. ET until 12:00 p.m. ET on November 10 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 77092041.

A simultaneous webcast of the call may be accessed by visiting www.endo.com.  In addition, a replay of the webcast will be available until 12:00 p.m. ET on November 10.  The replay can be accessed by clicking on "Events" in the Investor Relations section of the website.

About Endo

Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company with a diversified business model, operating in three key business segments - branded pharmaceuticals, generics and devices and services. We deliver an innovative suite of complementary products and services to meet the needs of patients in areas such as pain management, pelvic health, urology, endocrinology and oncology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries American Medical Systems, HealthTronics, Inc. and Qualitest Pharmaceuticals, please visit http://www.endo.com/.

SOURCE Endo Pharmaceuticals

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED